The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors
- PMID: 33076303
- PMCID: PMC7602474
- DOI: 10.3390/cancers12102983
The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors
Abstract
Checkpoint blockade immunotherapy (CPI) is an effective treatment option for many types of cancers. Irrespective of its wide clinical implications, the overall efficacy remains unpredictable and even poor in certain pathologies such as breast cancer. Thus, it is imperative to understand the role of factors affecting its responsiveness. In this review, we provide an overview on the involvement of sociological factors, lifestyles and metabolic disorders in modulating the CPI response in patients from multiple malignancies. Lifestyle habits including exercise, and diet promoted therapeutic responsiveness while alcohol consumption mitigated the CPI effect by decreasing mutational burden and hampering antigen presentation by dendritic cells. Metabolic disorder such as obesity was recognized to enhance the PD-1 expression while diabetes and hypertension were consequences of CPI therapy rather than causes. Among the sociologic factors, sex and race positively influenced the CPI effectiveness on account of increased effector T cell activity and increased PD-1 expression while ageing impaired CPI responsiveness by decreasing functional T cell and increased toxicity. The combined effect of these factors was observed for obesity and gender, in which obese males had the most significant effect of CPI. Therefore these variables should be carefully considered before treating patients with CPI for optimal treatment outcome.
Keywords: anti PD-L1; anti-CTLA; circadian rhythms; diabetes; diet; immunotherapy; obesity.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data.J Immunother Cancer. 2023 Feb;11(2):e006464. doi: 10.1136/jitc-2022-006464. J Immunother Cancer. 2023. PMID: 36822668 Free PMC article.
-
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.Eur Urol. 2019 Nov;76(5):599-603. doi: 10.1016/j.eururo.2019.06.025. Epub 2019 Jul 1. Eur Urol. 2019. PMID: 31272788 Free PMC article.
-
A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.Cancer Immunol Res. 2018 Oct;6(10):1136-1149. doi: 10.1158/2326-6066.CIR-18-0056. Epub 2018 Aug 21. Cancer Immunol Res. 2018. PMID: 30131376
-
Immune Checkpoint Blockade in Breast Cancer Therapy.Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18. Adv Exp Med Biol. 2017. PMID: 29282694 Review.
-
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.
Cited by
-
Tumor-intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint blockade in breast cancer.Mol Ther. 2024 Oct 2;32(10):3669-3682. doi: 10.1016/j.ymthe.2024.07.021. Epub 2024 Jul 31. Mol Ther. 2024. PMID: 39086134
-
The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance.Cancers (Basel). 2021 Nov 29;13(23):6012. doi: 10.3390/cancers13236012. Cancers (Basel). 2021. PMID: 34885122 Free PMC article. Review.
-
CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy.Cancer Cell Int. 2022 Jun 17;22(1):216. doi: 10.1186/s12935-022-02630-x. Cancer Cell Int. 2022. PMID: 35715855 Free PMC article.
-
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision.J Immunother Cancer. 2024 Jun 19;12(6):e009063. doi: 10.1136/jitc-2024-009063. J Immunother Cancer. 2024. PMID: 38901879 Free PMC article. Review.
-
Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis.Front Pharmacol. 2023 Mar 13;14:1111061. doi: 10.3389/fphar.2023.1111061. eCollection 2023. Front Pharmacol. 2023. PMID: 36992842 Free PMC article.
References
-
- Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000;192:1027–1034. doi: 10.1084/jem.192.7.1027. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials